December 19, 2016 / 4:24 PM / a year ago

BRIEF-U.S. FDA grants accelerated approval to new treatment for advanced ovarian cancer

Dec 19 (Reuters) - Source: U.S. Food and Drug Administration

* U.S. FDA grants accelerated approval to new treatment for advanced ovarian cancer

* U.S. FDA says also granted the Rubraca application breakthrough therapy designation and priority review status

* U.S. FDA says agency approved Rubraca under its accelerated approval program

* U.S. FDA says FDA also approved the FoundationFocus CDxBRCA companion diagnostic for use with Rubraca Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below